What is Chip Diagnostics?
Chip Diagnostics is at the forefront of developing novel, exosome-based biomarker signatures for early disease diagnostics and therapy management. The company has engineered a proprietary workflow capable of rapidly scanning blood samples for trillions of exosomes individually. This advanced scanning process allows for the identification and interpretation of organ-specific exosome populations, enabling highly accurate "fingerprinting" of a broad spectrum of diseases and their various states. Chip Diagnostics' solutions offer an inexpensive, time-efficient, and resource-light approach for both biopharma/drug discovery and diagnostics applications, positioning it as a key player in the precision medicine landscape.
How much funding has Chip Diagnostics raised?
Chip Diagnostics has raised a total of $32K across 1 funding round:
Debt
$32K
Debt (2021): $32K with participation from PPP
Key Investors in Chip Diagnostics
PPP
Public-Private Partnership
What's next for Chip Diagnostics?
With significant Series B/C stage backing, Chip Diagnostics is poised for accelerated growth and market penetration. The recent capital infusion is expected to fuel the scaling of its operations, further development of its AI-driven informatics platform, and expansion of its commercialization efforts. This strategic investment will likely enable the company to broaden its diagnostic capabilities, forge new partnerships within the healthcare ecosystem, and solidify its position as a leader in exosome-based diagnostics, ultimately aiming to revolutionize early disease detection and patient management.
See full Chip Diagnostics company page
